Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shidong Lv

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Molecular Biomedicine|November 17, 2025
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progressionHaoran Wen, Maierhaba Maheremu, Kaidi Zhang, et al.
The Journal of Pathology|October 6, 2025
KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancersYuedian Ye, Yuanpeng Liao, Yifan Zhang, et al.
Academic Radiology|January 3, 2025
An Automatic Deep-Radiomics Framework for Prostate Cancer Diagnosis and Stratification in Patients with Serum Prostate-Specific Antigen of 4.0-10.0 ng/mL: A Multicenter Retrospective StudyBowen Zheng, Futian Mo, Xiaoran Shi, et al.
The Journal of Clinical Investigation|December 17, 2020
Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancerShidong Lv, Qiong Song, Guang Chen, et al.
Oncogene|December 23, 2017
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4Shidong Lv, Liyan Ji, Bin Chen, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Molecular Biomedicine|November 17, 2025
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progressionHaoran Wen, Maierhaba Maheremu, Kaidi Zhang, et al.
The Journal of Pathology|October 6, 2025
KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancersYuedian Ye, Yuanpeng Liao, Yifan Zhang, et al.
Academic Radiology|January 3, 2025
An Automatic Deep-Radiomics Framework for Prostate Cancer Diagnosis and Stratification in Patients with Serum Prostate-Specific Antigen of 4.0-10.0 ng/mL: A Multicenter Retrospective StudyBowen Zheng, Futian Mo, Xiaoran Shi, et al.
The Journal of Clinical Investigation|December 17, 2020
Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancerShidong Lv, Qiong Song, Guang Chen, et al.
Oncogene|December 23, 2017
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4Shidong Lv, Liyan Ji, Bin Chen, et al.
Pageof 4